nderstanding drug concentrations in the body on the optimisation of sexually transmitted infections (STIs) treatments.

Not Applicable

Completed

• Conditions: Anorectal Chlamydia trachomatis (CT); Oropharyngeal Chlamydia trachomatis (CT); Infection - Sexually transmitted infections; Anorectal Neisseria gonorrhoeae (NG); Oropharyngeal Neisseria gonorrhoeae (NG)

• Registration Number: ACTRN12621000339853
• Lead Sponsor: niversity of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-25
• Study Completion: 2023-03-08
• Last Update Posted: 29 January 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

(1) Men or women aged 18 years or older who test positive for rectal and/or oropharyngeal infections with CT or NG (they cannot have both infections) using NAAT or culture methods OR (2) healthy (non-infected) men and women.

Both healthy and infected participants must have
(a) Adequate English and comprehension to give informed consent (b) Able to attend all follow up visits (c) Those with gingival or periodontal disease/caries are eligible since >30% of population have these conditions (d) Medicare card (e) fully vaccinated for COVID-19

Exclusion Criteria

(1) Oral antibiotic use in the last 4 weeks (2) widespread mucosal ulcerations by clinical examination. (3) Infection with both CT and NG) i.e. only single infections at one site are eligible (4) Infection at the same site with Mycoplama genitalium (5) Known contraindications or interactions with any of the treatments (6) Pregnant or breastfeeding women (7) Past participants in this trial (8) transgender people (9) HIV positive participants with CD4 counts less than 250 cells/mm3

Healthy, non-infected participants will not have other infections (CT and NG) including Mycoplama genitalium.

Study & Design

• Study Type: Interventional
• Study Design: Not specified